Role of cytokines in the pathogenesis of inflammatory bowel disease

Konstantinos Papadakis, Stephan R. Targan

Research output: Contribution to journalReview article

533 Citations (Scopus)

Abstract

Recent advances in the drug treatment of inflammatory bowel disease (IBD) have paralleled our understanding of the pathophysiology of ulcerative colitis and Crohn's disease. Several proinflammatory and immune-regulatory cytokines are upregulated in the mucosa of patients with IBD, and differences and similarities in the cytokine profiles of ulcerative colitis and Crohn's disease have been elucidated. Several clinical trials involving a chimeric anti-TNF-α (tumor necrosis factor-α) antibody have shown marked clinical benefit in the majority of patients with Crohn's disease, verifying the importance of TNF-α in the pathogenesis of Crohn's disease. In preliminary studies, treatment with recombinant human interleukin-10 has been beneficial in Crohn's disease but not in ulcerative colitis. Future treatment of IBD may include combination or sequential cytokine and anticytokine administration in defined groups of patients based on their mucosal cytokine profiles.

Original languageEnglish (US)
Pages (from-to)289-298
Number of pages10
JournalAnnual Review of Medicine
Volume51
DOIs
StatePublished - May 3 2000
Externally publishedYes

Fingerprint

Inflammatory Bowel Diseases
Crohn Disease
Cytokines
Ulcerative Colitis
Interleukin-10
Drug therapy
Mucous Membrane
Therapeutics
Tumor Necrosis Factor-alpha
Clinical Trials
Antibodies
Pharmaceutical Preparations

Keywords

  • Crohn's disease
  • Interleukin-10
  • Treatment
  • Tumor necrosis factor-α
  • Ulcerative colitis

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Role of cytokines in the pathogenesis of inflammatory bowel disease. / Papadakis, Konstantinos; Targan, Stephan R.

In: Annual Review of Medicine, Vol. 51, 03.05.2000, p. 289-298.

Research output: Contribution to journalReview article

@article{af7701c657aa4405805ab8441f9ab18a,
title = "Role of cytokines in the pathogenesis of inflammatory bowel disease",
abstract = "Recent advances in the drug treatment of inflammatory bowel disease (IBD) have paralleled our understanding of the pathophysiology of ulcerative colitis and Crohn's disease. Several proinflammatory and immune-regulatory cytokines are upregulated in the mucosa of patients with IBD, and differences and similarities in the cytokine profiles of ulcerative colitis and Crohn's disease have been elucidated. Several clinical trials involving a chimeric anti-TNF-α (tumor necrosis factor-α) antibody have shown marked clinical benefit in the majority of patients with Crohn's disease, verifying the importance of TNF-α in the pathogenesis of Crohn's disease. In preliminary studies, treatment with recombinant human interleukin-10 has been beneficial in Crohn's disease but not in ulcerative colitis. Future treatment of IBD may include combination or sequential cytokine and anticytokine administration in defined groups of patients based on their mucosal cytokine profiles.",
keywords = "Crohn's disease, Interleukin-10, Treatment, Tumor necrosis factor-α, Ulcerative colitis",
author = "Konstantinos Papadakis and Targan, {Stephan R.}",
year = "2000",
month = "5",
day = "3",
doi = "10.1146/annurev.med.51.1.289",
language = "English (US)",
volume = "51",
pages = "289--298",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Role of cytokines in the pathogenesis of inflammatory bowel disease

AU - Papadakis, Konstantinos

AU - Targan, Stephan R.

PY - 2000/5/3

Y1 - 2000/5/3

N2 - Recent advances in the drug treatment of inflammatory bowel disease (IBD) have paralleled our understanding of the pathophysiology of ulcerative colitis and Crohn's disease. Several proinflammatory and immune-regulatory cytokines are upregulated in the mucosa of patients with IBD, and differences and similarities in the cytokine profiles of ulcerative colitis and Crohn's disease have been elucidated. Several clinical trials involving a chimeric anti-TNF-α (tumor necrosis factor-α) antibody have shown marked clinical benefit in the majority of patients with Crohn's disease, verifying the importance of TNF-α in the pathogenesis of Crohn's disease. In preliminary studies, treatment with recombinant human interleukin-10 has been beneficial in Crohn's disease but not in ulcerative colitis. Future treatment of IBD may include combination or sequential cytokine and anticytokine administration in defined groups of patients based on their mucosal cytokine profiles.

AB - Recent advances in the drug treatment of inflammatory bowel disease (IBD) have paralleled our understanding of the pathophysiology of ulcerative colitis and Crohn's disease. Several proinflammatory and immune-regulatory cytokines are upregulated in the mucosa of patients with IBD, and differences and similarities in the cytokine profiles of ulcerative colitis and Crohn's disease have been elucidated. Several clinical trials involving a chimeric anti-TNF-α (tumor necrosis factor-α) antibody have shown marked clinical benefit in the majority of patients with Crohn's disease, verifying the importance of TNF-α in the pathogenesis of Crohn's disease. In preliminary studies, treatment with recombinant human interleukin-10 has been beneficial in Crohn's disease but not in ulcerative colitis. Future treatment of IBD may include combination or sequential cytokine and anticytokine administration in defined groups of patients based on their mucosal cytokine profiles.

KW - Crohn's disease

KW - Interleukin-10

KW - Treatment

KW - Tumor necrosis factor-α

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=0034005581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034005581&partnerID=8YFLogxK

U2 - 10.1146/annurev.med.51.1.289

DO - 10.1146/annurev.med.51.1.289

M3 - Review article

VL - 51

SP - 289

EP - 298

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -